[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535186":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":50,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":18,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PD-1 inhibitor adjuvant therapy group","EXPERIMENTAL","Received adjuvant PD-1 inhibitor 2-4 weeks after microwave surgery for a total of 9 cycles of treatment",[13],"Drug: PD-1 Inhibitors",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Receive regular monitoring and follow-up",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","PD-1 Inhibitors","Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles",[9],[26],{"name":27,"affiliation":5,"role":28},"WanGuang D Zhang","STUDY_DIRECTOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","+8613886195965","wgzhang@tjh.tjmu.edu.cn",[35],{"facility":36,"status":37,"city":38,"state":18,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","RECRUITING","Wuhan","430000","China","CN",{"type":43,"coordinates":44},"Point",[45,46],114.26667,30.58333,{"lat":46,"lon":45},[49],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Chen Xiaoping","professor","100535186","adjuvant-pd-1-inhibitor-for-patients-with-early-stage-hepatocellular-carcinoma-following-microwave-ablation-100535186",false,"NCT06248554","Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation","Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation: a Prospective Cohort Study","Inclusion Criteria:\n\n* Aged 18-75 years\n* Pathological type is HCC, BCLC stage 0-A\n* No extrahepatic HCC\n* No radiographic recurrence at 2-4 weeks after ablation\n* Eastern Cooperative Oncology Group (ECOG) performing status of 0-1\n* Child-Pugh grade A or B and adequate hematologic and organ function\n\nExclusion Criteria:\n\n* Any history of other malignant tumors or recurrent HCC\n* Any preoperative treatment for HCC including local and systemic therapy\n* Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency\n* Any persistent serious ablation-related complications\n* Esophageal and\u002For gastric variceal bleeding within 6 months\n* Inability or refusal to comply with the treatment and monitoring\n* Participation in other clinical trials","ALL","18 Years","75 Years",{"count":65,"type":66},200,"ESTIMATED","INTERVENTIONAL",[69],"NA","For early-stage hepatocellular carcinoma, i.e. Barcelona Clinical Liver Cancer Stage 0, ablation is the standard treatment with a comparable prognosis and less risk of ablation compared with liver resection. However, ablation is demanding on the surgeon and patients often face early recurrence if ablation is not complete. Therefore, it is necessary to find reasonable adjuvant treatment to consolidate the effect of microwave therapy.",[72],"Hepatocellular Carcinoma",[74,75,76,77],"Hepatocellular carcinoma","Adjuvant therapy","Microwave ablation","PD-1 inhibitor","2025-11-29",{"date":80,"type":81},"2025-12-02","ACTUAL",{"date":83,"type":81},"2019-12-01",{"date":85,"type":66},"2025-12-31",{"name":52,"class":6},1]